About MiroBio
MiroBio is a Healthcare company based in Oxford (United Kingdom) founded in 2019 by Simon Davis and Richard Cornall, and was acquired by Gilead in August 2022. MiroBio has raised $131.81 million across 3 funding rounds from investors including Gilead, Orbimed and Medicxi. The company has 29 employees. MiroBio was last valued at $25.5 million in April 2022. Its chief executive, as recorded, is Eliot Charles. Its focus areas include Life Sciences, Immunology, Drugs and Autoimmune Diseases. Its legal entity is MIROBIO LTD.
Company details
Developer of therapeutics for auto-immune diseases. The company has developed a platform to develop antibiotics that activate natural mechanisms to control over-active immune responses that cause these diseases.
- Headquarters Oxford, United Kingdom
- Employees 29
- Founders Simon Davis, Richard Cornall
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website mirobio.com
- Social LinkedIn
- Acquired by Gilead (Aug 2022)
- Legal Name Mirobio Ltd
- Date of Incorporation 08 Oct, 2018
- Jurisdiction GARSINGTON, OXFORD, UNITED KINGDOM
Funding Insights of MiroBio
MiroBio has successfully raised a total of $131.81M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $97 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $131.81M
- Total Rounds 3
- Last Round Series B — $97M
- First Round $34M
(Apr 2019)
- Investors Count 7
All 3 funding rounds of MiroBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $97M | Series B | – | Medicxi | |
| Apr 2022 | $811,110 | Series A | $25.5M | – | – |
| Apr 2019 | $34M | Series A | – | Oxford Science Enterprises, Samsara BioCapital |
| Date | Valuation | Stage |
|---|---|---|
| Apr 2022 | $25.5M | •••••••• |
Last known valuation $25.5M (Apr 2022). 8 investors in total: 8 institutional.
Investors in MiroBio
MiroBio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Gilead, Orbimed and Medicxi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage life science focused VC firm investing in geographies such as Europe and the US | medicxi.com | London, United Kingdom | ||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom | ||
Investment management services for science ventures are provided in Oxford. | oxfordscienceenterprises.com | Oxford, United Kingdom | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Monograph Capital is focused on life sciences investment. | monograph.bio | |||
Venture capital funding is provided by Samsara BioCapital in California. | samsaracap.com | Palo Alto, United States | ||
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | gilead.com | Foster City, United States |
Investor details for MiroBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MiroBio
889 people are tracked at MiroBio (562 in leadership, 9 in board & advisors, 318 in team); the tracked headcount is 29.
| Name | Role | Group |
|---|---|---|
Simon Davis | Co-Founder | Leadership |
Richard Cornall | Co-Founder | Leadership |
Eliot Charles | CEO | Leadership |
Ambika Rana | Associate Director, Data Science | Leadership |
Rebecca Gledhill | Senior Manager, People Partner EMEA | Leadership |
Rie Devert | Senior Director, Patient Safety | Leadership |
Herman Wong | Director, Global Medical Information | Leadership |
Erin Burkhart | Senior Vice President, Controller & Chief Accounting Officer | Leadership |
Cesar Garcia Gonzalez | Business Analytics Associate Director | Leadership |
Jaymin Mehta | Vice President, Global Commercial Head Of Liver, Inflammation, Covid-19, And Established Products | Leadership |
Lucy Guest | Associate Director, Regulatory Operations | Leadership |
Rajesh Ravikumar | Associate Director, Integrated Insights And Analytics | Leadership |
Vimal Unewal Supply Chain Leader | Director, Trade Operations Uk/ire | Leadership |
Joni Kane | Director | Leadership |
Henriette Burghoorn | Associate Director, Market Access | Leadership |
Christine T. | Associate Director, Disability Inclusion & Strategic Projects | Leadership |
J.c. Andry | Director, Medical Excellence - Global Medical Strategy & Operations | Leadership |
Jonathan Israel | Associate Director, Business Analytics & Commercial Excellence | Leadership |
Kristen Pela | Head Of Learning, Communications & Knowledge Management | Leadership |
Simon L. | Director, Strategic Projects, CEO Office | Leadership |
869 more people are available in the full profile.
Complete people profiles for MiroBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MiroBio
5 dated milestones of MiroBio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded MiroBio is founded.
- Funding First funding round of $34.0M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B, of $97.0M.
- Exit Acquired by Gilead.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mirobio
Complete news archive for MiroBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MiroBio
MiroBio was founded in 2019.
MiroBio is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Eliot Charles is the CEO of MiroBio, as recorded in our data.
MiroBio is a funded company, having raised a total of $131.81M across 3 funding rounds to date. The company's 1st funding round was a Series A of $34M, raised on Apr 2019.
MiroBio has 29 employees.
Developer of therapeutics for auto-immune diseases. The company has developed a platform to develop antibiotics that activate natural mechanisms to control over-active immune responses that cause these diseases.
MiroBio has 8 investors. Key investors include Gilead, Orbimed, Medicxi, SR One, and Advent Life Sciences.
The valuation of MiroBio is $25.5M as of Apr 2022.
MiroBio operates through Mirobio Ltd.
Yes. MiroBio was acquired by Gilead in August 2022.